CGON (CG Oncology) Inventories, Raw Materials & Components : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Inventories, Raw Materials & Components?

CG Oncology's inventories, raw materials & components for the quarter that ended in Sep. 2024 was $0.00 Mil.

CG Oncology Inventories, Raw Materials & Components Historical Data

The historical data trend for CG Oncology's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Inventories, Raw Materials & Components Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Inventories, Raw Materials & Components

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Raw Materials & Components	Get a 7-Day Free Trial					-	-	-	-	-

CG Oncology Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Inventories, Raw Materials & Components

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.